Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

Olsson, Anders; Istad, Helge; Luurila, O; Ose, Leiv; Stender, Steen; Tuomilehto, Jaakko; Wiklund, Olov; Southworth, Harry; Pears, John; Wilpshaar, J.W.

doi:10.1067/mhj.2002.128049

Cited by 160 publications

(140 citation statements)

References 18 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…In the J-LIT study, an increasing trend was observed by simvastatin for long-term treatment 4) . On the other hand, in long-term treatment studies of other statins, increasing trends of HDL-C were not observed 16) ; therefore, increasing effects on HDL-C might be different among statins in long-term treatment.…”

Section: Discussionmentioning

confidence: 99%

Effects of Pitavastatin (LIVALO Tablet) on High Density Lipoprotein Cholesterol (HDL-C) in Hypercholesterolemia Sub-Analysis of LIVALO Effectiveness and Safety (LIVES) Study

Teramoto

Shimano

Yokote

et al. 2009

JAT

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Pitavastatin (LIVALO Tablet) on High Density Lipoprotein Cholesterol (HDL-C) in Hypercholesterolemia Sub-Analysis of LIVALO Effectiveness and Safety (LIVES) Study

Teramoto

Shimano

Yokote

et al. 2009

JAT

View full text Add to dashboard Cite

show abstract

“…However, as the predicted cholesterol reduction is used to generate the probabilities of events in the long-term model, the authors are assuming that the maximum reduction achieved at 6 weeks is held constant over the horizon modelled. Evidence for rosuvastatin is available from studies of 52 weeks' duration (Olsson 125 and Brown 126 ), and a comparison of results with a discussion demonstrating the validity of using very short-term evidence to extrapolate over 20 years would increase the authenticity of the assumption made.…”

Section: Summary Of Effectiveness Datamentioning

confidence: 99%

“…In both studies, each statin was started at the lowest stated dose, and this dose was maintained for a 12-week period. During the following 40-week period, the dose could be sequentially doubled at weeks 12, 20, 28, 36 and 44 in study 4522IL/0026, 125 and at In study 4522IL/0026, mean doses over the 40-week titration period were as follows:…”

Section: Direct Statin-statin Comparisonsmentioning

confidence: 99%

“…90 (For further details of these studies, see Appendix 12. ) A further two studies of 6 months or longer were identified which compared the LDL-C-lowering efficacy of rosuvastatin (5 and 10 mg) with that of atorvastatin in patients with hypercholesterolaemia in northern Europe (study 4522IL/0026 125 ) and with that of pravastatin or simvastatin in similar patients in the USA (study 4522IL/0028 126 ). These studies did not report clinical outcomes.…”

Section: Direct Statin-statin Comparisonsmentioning

confidence: 99%

“…Only two of the events associated with rosuvastatin were considered serious (rectal haemorrhage and serum creatinine elevation). 125 In the other study, no SAEs were reported in patients receiving rosuvastatin.…”

mentioning

confidence: 99%

See 2 more Smart Citations

A systematic review and economic evaluation of statins for the prevention of coronary events

Ward

Jones²,

Pandor³

et al. 2007

Health Technol Assess

346

312

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

show abstract

Lipid lowering efficacy of atorvastatin

Adams

Tsang

Wright

2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

Cited by 160 publications

References 18 publications

Effects of Pitavastatin (LIVALO Tablet) on High Density Lipoprotein Cholesterol (HDL-C) in Hypercholesterolemia Sub-Analysis of LIVALO Effectiveness and Safety (LIVES) Study

Effects of Pitavastatin (LIVALO Tablet) on High Density Lipoprotein Cholesterol (HDL-C) in Hypercholesterolemia Sub-Analysis of LIVALO Effectiveness and Safety (LIVES) Study

A systematic review and economic evaluation of statins for the prevention of coronary events

Lipid lowering efficacy of atorvastatin

Contact Info

Product

Resources

About